Answers are grounded in this paper and cite their sources.
Background: Background: Aromatase inhibitors, Arimidex (anastrozole) and Femara (letrozole), are commonly used in the treatment of hormone receptor-positive (HR+) breast cancer in postmenopausal women. Despite similar efficacy, these drugs have different side effect profiles that impact patient compliance and quality of life.Objective: To compare the incidence and severity of side effects between Arimidex and Femara in postmenopausal women with HR+ breast cancer.Methods: A retrospective cohort study was conducted involving 1,000 postmenopausal women with HR+ breast cancer from multiple oncology centers. Participants were divided into two groups: Arimidex (n=500) and Femara (n=500). Side effects were assessed via patient self-reports, clinical evaluations, and standardized questionnaires. Data were analyzed using chi-square tests, t-tests, and logistic regression models, with p-values <0.05 considered significant.Results: Arimidex was associated with higher rates of joint pain (45% vs. 30%, p<0.001) and muscle pain (38% vs. 25%, p<0.01). Femara showed increased rates of hypertension (28% vs. 20%, p<0.05) and significant bone density loss (18% vs. 12%, p<0.05).Conclusion: Arimidex and Femara exhibit distinct side effect profiles, suggesting the need for personalized treatment approaches based on patient risk factors.
No takes yet. Share an insight, caveat, or question.
Rafique et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: